Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: Old problem - New Dilemma

Pediatric Blood and Cancer

Volumn 57, Issue 1, 2011, Pages 30-35

  Pana, Zoe Dorothea ^a   Roilides, Emmanuel ^b  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Itraconazole; Leukemia; Posaconazole; Vinca alkaloids; Voriconazole

Indexed keywords

AMINOTRANSFERASE; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DALFOPRISTIN; DRUG METABOLITE; FLUCONAZOLE; FOLINIC ACID; GLUTAMIC ACID; ITRACONAZOLE; POSACONAZOLE; PYRIDOXINE; QUINUPRISTIN; TRIAZOLE DERIVATIVE; VALSPODAR; VERAPAMIL; VINCRISTINE; VORICONAZOLE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTONOMIC NEUROPATHY; BONE MARROW SUPPRESSION; BRAIN DISEASE; CONSTIPATION; DEEP TENDON REFLEX; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; EWING SARCOMA; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HODGKIN DISEASE; HUMAN; HYPERTENSION; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LETHARGY; LIMB WEAKNESS; MOTOR DYSFUNCTION; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEPHROBLASTOMA; NEURITIS; NEUROBLASTOMA; NEUROGENIC BLADDER; NEUROPATHY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PARALYTIC ILEUS; PARESTHESIA; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PTOSIS; REVIEW; SEIZURE; SIDE EFFECT; SOFT TISSUE SARCOMA; TENDON REFLEX; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING; WEAKNESS;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HEMATOLOGIC NEOPLASMS; HUMANS; ITRACONAZOLE; RISK FACTORS; VINCRISTINE;

EID: 79955705339     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22972     Document Type: Review

References (51)

1. Böhme A, Ganser A, Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol 1995;71:311-312.
2. Gillies J, Hung K, Fitzsimons E, et al. Severe vincristine toxicity in combination with itraconazole. Clin Lab Haematol 1998;20:123-124.
3. Murphy JA, Ross LM, Gibson BE. Vincristine toxicity in five children with lymphoblastic leukemia. Lancet 1995;346:443.
4. Jeng M, Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukaemia. Pediatr Hematol Oncol 2001;18:137-142.
5. Sathiapalan RK, Al-Nasser A, El-Solh H, et al. Vincristine-itraconazole interaction: Cause for increasing concern. J Pediatr Hematol Oncol 2002;24:591.
6. Bermúdez M, Fuster JL, Llinares E, et al. Itraconazole-related increased Vincristine neurotoxicity: Case report and review of literature. Am J Pediatr Hematol Oncol 2005;27:389-392.
7. Ariffin H, Omar K, Ang E, et al. Severe vincristine neurotoxicity with concomitant use of itraconazole. J Pediatr Child Health 2003;39:638-640.
8. Kamaluddin M, Mc Nally P, Breatnach F, et al. Potentiation of Vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 2001;90:1204-1207.
9. Grigull L, Beier R, Schrauder A, et al. Invasive fungal infections are responsible for one-fifth of the infectious deaths in children with ALL. Mycoses 2003;46:441-446.
10. Zaoutis TE, Heydon K, Chu JH, et al. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States. Pediatrics 2006;117:711-716.
11. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 2006;91:1068-1075.
12. Kami M, Machida U, Okuzumi K, et al. Effect of fluconazole prophylaxis on fungal blood cultures: An autopsybased study involving 720 patients with haematological malignancy. Br J Haematol 2002;117:40-46.
13. Kume H, Yamazaki T, Abe M, et al. Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: Comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Path Intern 2003;53:744-750.
14. Girmenia C, Pagano L, Corvatta L, et al. The epidemiology of fusariosis in patients with haematological diseases. GIMEMA Infection Programme. Br J Haematol 2000;111:272-276.
15. Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008;14:5-24.
16. Pandya NA, Atra A, Riley U, et al. Role of itraconazole in haematology/oncology. Arch Dis Child 2003;88:258-260.
17. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 1999;24:1089-1093.
18. Wood A. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994;330:263-272.
19. Lehrnbecher T, Mousset S, Sörensen J, et al. Current practice of antifungal prophylaxis and treatment in immunocompromised children and adults with malignancies: A single centre approach. Mycoses 2009;52:107-117.
20. Poirer JM, Cheymol G. Optimization of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998;35:461-473.
21. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in surperficial and systemic mycoses. Drugs 1989;37:310-344.
22. Heykants J, Van Peer A, Van De Velde V, et al. The clinical pharmacokinetics of itraconazole: An overview. Mycoses 1989;32:67-87.
23. de Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001;61:27-37.
24. Gomber S, Dewan P, Chhonker D. Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr 2010;77:97-100.
25. Estlin EJ, Ronghe M, Burke GA, et al. The clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia. Br J Haematol 2000;110:780-790.
26. Chessels JM. The management of high risk lymphoblastic leukemia in children. Br J Hematol 2000;108:204-216.
27. Pieters R, Huismans DR, Leyva A, et al. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett 1988;41:323-332.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
29. Lautier D, Canitrot Y, Deeley RG, et al. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 1996;52:967-977.
30. Sahenk Z, Brandy ST, Mendell JR. Studies on the pathogenesis of vincristine induced neuropathy. Muscle Nerve 1987;10:80-84.
31. Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol 1986;1:421-427.
32. Jackson DV, Mc Mahan RA, Pope EK, et al. Clinical trial of pyridoxine to reduce vincristine neurotoxicity. J Neurooncol 1986;4:37-41.
33. Jackson DV, Mc Mahan RA, Pope EK, et al. Clinical trial of folinic acid to reduce vincristine neurotoxicity. Cancer Chemother Pharmacol 1986;17:281-284.
34. Mokhtar GM, Shaaban SY, Elbarbary NS, et al. A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: A pilot study. J Pediatr Hematol Oncol 2010;32:594-600.
35. Sathiapalan RK, El-Solh H. Enhanced vincristine neurotoxicity from drug interactions: Case report and review of literature. Pediatr Hematol Oncol 2001;18:543-546.
36. Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 2009;48:1441-1458.
37. Renbarger JL, McCammack KC, Rouse CE, et al. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008;50:769-771.
38. Bashir H, Motl S, Metzger ML, et al. Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma. J Pediatr Hematol Oncol 2006;28:33-35.
39. Takahashi N, Kameoka Y, Yamanaka Y, et al. Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma. Intern Med 2008;47:651-653.
40. Chen S, Wu D, Sun A. Itraconazole-enhanced vindesine neurotoxicity in adult acute lymphoblastic leukaemia. Am J Hematol 2007;82:942.
41. Eiden C, Palenzuela G, Hillaire-Buys D, et al. Posaconazole-increased vincristine neurotoxicity in a child: A case report. J Pediatr Hematol Oncol 2009;31:292-295.
42. Jain S, Kapoor G. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine. Pediatr Blood Cancer 2010;54:783.
43. Mantadakis E, Amoiridis G, Kondi A, et al. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J Pediatr Hematol Oncol 2007;29:130.
44. Cronin S, Chandrasekar PH. Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 2010;65:410-416.
45. Anaissie EJ, Kontoyiannis DP, Huls C, et al. Safety, plasma concentrations, and safety of high-dose fluconazole in invasive mold infections. J Infect Dis 1995;172:599-602.
46. Hope WW, Billaud EM, Lestner J, et al. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis 2008;12:580-586.
47. Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract 2009;15:175-182.
48. Whittle AM, Ali S. Primary prophylaxis with voriconazole in patients receiving induction chemotherapy on the MRC adult acute lymphoblastic leukaemia trial (UK-ALL XII) to avoid itraconazole-enhanced vinca neurotoxicity. Int J Lab Hematol 2008;30:173-174.
49. Moore A, Pinkerton R. Vincristine: Can its therapeutic index be enhanced? Pediatr Blood Cancer 2009;53:1180-1187.
50. Haim N, Epelbaum R, Ben-Shahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994;73:2515-2519.
51. Worth LJ. RE: Azoles and vincristine dosing recommendations. Pers Commun 2009.